Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by N. V. Frey
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Clinical Cancer Research
Cancer Research
Oncology
Related publications
A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients With Relapsed Non Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
The mTOR Inhibitor Everolimus in Combination With Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase Ib/Ii Study
Oncotarget
Oncology
Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
A Multi-Center Phase I Study of Clofarabine, Etoposide and Cyclophosphamide in Combination in Pediatric Patients With Refractory or Relapsed Acute Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
Clinical Hematology International
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
Clinical Cancer Research
Cancer Research
Oncology
